XML 31 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
Supplemental Financial Information
 12 Months Ended
Dec. 31, 2023
Disclosure Text Block Supplement [Abstract]  
Supplemental Financial Information Supplemental Financial Information
Other (income) expense, net, for 2023, 2022 and 2021 includes approximately $498 million, $406 million and $270 million of income, respectively, related to the non-service cost components of the net periodic benefit costs associated with the pension and post-retirement medical plans.
The following summarizes the activity related to the allowance for doubtful accounts:
(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, 2021$313 
Provisions/charges to income6 
Amounts charged off and other deductions(57)
Balance at December 31, 2022262 
Provisions/charges to income26 
Amounts charged off and other deductions(47)
Balance at December 31, 2023$241 
The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.
The detail of various balance sheet components is as follows:
(in millions)December 31,
2023		December 31,
2022
Long-term Investments:
Equity securities$555 $558 
Other244 208 
Total$799 $766 
The increase in Abbott’s long-term investments as of December 31, 2023 versus the balance as of December 31, 2022 is primarily due to investments acquired as part of a business acquisition and other additional investments, partially offset by the impact of equity method investment losses.
Abbott’s equity securities as of December 31, 2023 and December 31, 2022, include $314 million and $298 million, respectively, of investments in mutual funds that are held in a rabbi trust acquired as part of the St. Jude Medical, Inc. (St. Jude Medical) business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.
Abbott also holds certain investments as of December 31, 2023 with a carrying value of $141 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of $88 million that do not have a readily determinable fair value.
(in millions)December 31,
2023		December 31,
2022
Other Accrued Liabilities:
Accrued rebates payable to government agencies$650 $638 
Accrued other rebates (a)1,091 1,087 
All other 3,681 4,120 
Total$5,422 $5,845 
________________________________________________________
(a)
Accrued wholesaler chargeback rebates of $232 million and $234 million at December 31, 2023 and 2022, respectively, are netted in trade receivables because Abbott’s customers are invoiced at a higher catalog price but only remit to Abbott their contract price for the products.
(in millions)December 31,
2023		December 31,
2022
Post-employment Obligations and Other Long-term Liabilities:
Defined benefit pension plans and post-employment medical and dental plans for significant plans$1,964 $1,784 
Deferred income taxes568 991 
Operating lease liabilities949 943 
All other (b)3,466 3,804 
Total$6,947 $7,522 
________________________________________________________
(b)
Includes approximately $650 million and $850 million of net unrecognized tax benefits and $430 million and $740 million of transition tax obligation related to the TCJA in 2023 and 2022, respectively.